Rxivist logo

Heterologous vaccination strategy for containing COVID-19 pandemic

By Ang Lin, Jingjing Liu, Xiaopin Ma, Fanfan Zhao, Bo Yu, Jiaxin He, Mingyun Shen, Lei Huang, Hongming Tang, Erpeng Jiang, Yue Wang, Pingfang Cui, Yujiang Zhang, Weiguo Yao, Aihua Zhang, Youchun Wang, Yuhua Li, Weijin Huang, Qihan Li, Zhongmin Liu, Hangwen Li

Posted 23 May 2021
medRxiv DOI: 10.1101/2021.05.17.21257134

An unequitable vaccine allocation and continuously emerging SARS-CoV-2 variants pose challenges to contain the pandemic, which underscores the need for licensing more vaccine candidates, increasing manufacturing capacity and implementing better immunization strategy. Here, we report data from a proof-of-concept investigation in two healthy individuals who received two doses of inactivated whole-virus COVID-19 vaccines, followed by a single heterologous boost vaccination after 7 months with an mRNA vaccine candidate (LPP-Spike-mRNA) developed by Stemirna Therapeutics. Following the boost, Spike-specific antibody (Ab), memory B cell and T cell responses were significantly increased. These findings indicate that a heterologous immunization strategy combining inactivated and mRNA vaccines can generate robust vaccine responses and therefore provide a rational and effective vaccination regimen.

Download data

  • Downloaded 3,607 times
  • Download rankings, all-time:
    • Site-wide: 5,408
    • In infectious diseases: 1,085
  • Year to date:
    • Site-wide: 18,310
  • Since beginning of last month:
    • Site-wide: 35,340

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide